RGEN:NASDAQ
Repligen Corp
$172.51
arrow_downward
-0.79%(-1.37) 1D
$172.51
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 12, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RGEN...
Open
$171.73
High
$173.82
Low
$169.90
Mkt. cap
10.95B
Avg. vol.
1.20M
Volume
0.00
P/E ratio
235.15
52-wk high
$198.86
52-wk low
$100.99
EPS
$0.73
Beta
1.08
Shares outstanding
63.49M
No. of employees
2K
Open
$171.73
High
$173.82
Low
$169.90
Mkt. cap
10.95B
Avg. vol.
1.20M
Volume
0.00
P/E ratio
235.15
52-wk high
$198.86
52-wk low
$100.99
EPS
$0.73
Beta
1.08
Shares outstanding
63.49M
No. of employees
2K
News stories
From web sources and news partners
Investing.com Canada
·
16 hours ago
Form 144 REPLIGEN CORP For: 12 October By Investing.com
Simply Wall Street
·
1 day ago
Does Repligen (RGEN) Look Fully Valued After The BioLife Deal?
Profile
Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN. Wikipedia
About Repligen Corp
CEOTony J. Hunt
Employees2K
Founded1981
HeadquartersWaltham, Massachusetts, United States
SectorHealth care
Websiterepligen.com